Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 2/20 | 0.33 |
| ▸ | PARG | Q86W56 | 3/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
| ▸ | PDE9A | O76083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16647245 | 1.00 | CYP4F2 (0.39) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL26674786 | 0.94 | RXRA (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30641330 | 0.94 | RXRA (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL29478948 | 0.88 | RXRA (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL21393943 | 0.88 | RXRA (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL25795327 | 0.88 | RXRA (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL23043733 | 0.87 | CYP4F2 (0.39) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30848411 | 0.87 | CYP4F2 (0.36) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL24373802 | 0.86 | RXRA (0.37) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL21379252 | 0.85 | RXRA (0.37) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581024-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | Jazz Pharmaceuticals Ireland Limited (IE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025078984-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS KRAS DEGRADERS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-04-17 | — | — | WO | disclosed |
| EP-4526293-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Repare Therapeutics Inc. (CA) | 2025-03-26 | — | — | EP | disclosed |
| EP-4352061-A1 | QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITIORS | Redx Pharma Plc (GB) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024047135-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-03-07 | — | — | WO | disclosed |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2023220831-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-23 | — | — | WO | disclosed |
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4232444-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022258974-A1 | QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITIORS | REDX PHARMA PLC (GB) | 2022-12-15 | — | — | WO | disclosed |
| EP-4087843-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2022-11-16 | — | — | EP | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022083616-A9 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | 贝达药业股份有限公司 | 2022-05-27 | — | — | WO | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022083616-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | 贝达药业股份有限公司 | 2022-04-28 | — | — | WO | disclosed |
| CN-110267957-B | Quinazoline compounds | 安斯泰来制药株式会社 | 2022-04-26 | — | — | CN | disclosed |
| CN-114040914-A | Quinazolinone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | CYP4F2 3372/4885CYP4A11 2590/4885RXRA 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.